699P Atezolizumab monotherapy in cisplatin-ineligible patients with previously untreated metastatic urothelial carcinoma: 5-year response and survival analysis from the phase II IMvigor210 study (cohort 1)

Cisplatin-based chemotherapy is the standard of care for first-line (1L) metastatic urothelial carcinoma (mUC), although many patients (pts) are ineligible for treatment with cisplatin. Cohort 1 of the single-arm phase II IMvigor210 study evaluated the efficacy and safety of 1L atezolizumab (atezo, anti–PD-L1) in cisplatin-ineligible pts with mUC (Balar Lancet 2017) and demonstrated sustained responses with longer follow-up (Loriot ASCO 2019)....